RECOVERY, supported by NIHR (National Institute for Health Research) has found out that Dexamethasone, a steroid can help in reducing the fatality rate due to Coronavirus.
According to the experts, the low-dose steroid treatment dexamethasone is a major breakthrough in the fight against the deadly virus and can be of huge benefit for poor countries with a high number of COVID cases.
It is said that Dexamethasone can help in reducing the risk of death by a third for patients on ventilators and by fifth for those on oxygen.
During the trial, 2104 patients were given dexamethasone once per day for ten days and were compared with 4321 patients under usual treatment.
Among the 4321 usual treatment group, 28-day mortality was highest in those on ventilators (41%), intermediate in those on oxygen only (25%), and lowest among those who were not receiving any respiratory intervention (13%).
Prof Chris Whitty, Chief Medical Officer for England and co-leader of the NIHR said:
“This is the most important trial result for COVID-19 so far. Is shows significant reduction in mortality in those requiring oxygen or ventilation from a widely available, safe and well known drug. We should all be grateful to the patients who volunteered and those who made this trial possible. It will save lives around the world.” (Source: NIHR)
RECOVERY, established in March 2020 is a randomised clinical trial to test a range of potential treatments for COVID-19.
For the time being, Dexamethasone trials will be done only in the UK through NIHR’s Clinical Research Network. NIHR says over 11,500 patients have enrolled into RECOVERY from over 175 NHS hospitals.
COVID has killed more than 4,30,000 people globally.